BMJ  2004;329:15-19 (3 July), doi:10.1136/bmj.329.7456.15

Paper

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Munir Pirmohamed, professor of clinical pharmacology1, Sally James, research pharmacist3, Shaun Meakin, research nurse2, Chris Green, senior pharmacist2, Andrew K Scott, consultant in care of the elderly3, Thomas J Walley, professor of clinical pharmacology1, Keith Farrar, chief pharmacist3, B Kevin Park, professor of pharmacology1, Alasdair M Breckenridge, professor of clinical pharmacology1

1 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE, 2 Royal Liverpool University Hospital, Liverpool L7 8XP, 3 Wirral Hospitals NHS Trust, Wirral CH49 5PE

Correspondence to: M Pirmohamed munirp{at}liv.ac.uk

Abstract

Objective To ascertain the current burden of adverse drug reactions (ADRs) through a prospective analysis of all admissions to hospital.

Design Prospective observational study.

Setting Two large general hospitals in Merseyside, England.

Participants 18 820 patients aged > 16 years admitted over six months and assessed for cause of admission.

Main outcome measures Prevalence of admissions due to an ADR, length of stay, avoidability, and outcome.

Results There were 1225 admissions related to an ADR, giving a prevalence of 6.5%, with the ADR directly leading to the admission in 80% of cases. The median bed stay was eight days, accounting for 4% of the hospital bed capacity. The projected annual cost of such admissions to the NHS is £466m ({euro}706m, $847m). The overall fatality was 0.15%. Most reactions were either definitely or possibly avoidable. Drugs most commonly implicated in causing these admissions included low dose aspirin, diuretics, warfarin, and non-steroidal anti-inflammatory drugs other than aspirin, the most common reaction being gastrointestinal bleeding.

Conclusion The burden of ADRs on the NHS is high, accounting for considerable morbidity, mortality, and extra costs. Although many of the implicated drugs have proved benefit, measures need to be put into place to reduce the burden of ADRs and thereby further improve the benefit:harm ratio of the drugs.

Introduction

Lazarou and colleagues suggested that adverse drug reactions (ADRs) caused over 100 000 deaths in the United States in 1994.1 However, this study was criticised for various reasons, including that the death rate was extrapolated from admission rates in 1994, yet based on rates of ADRs taken from studies conducted before 1981.2 Publication bias may have also contributed to what many investigators regard as inflated mortality data.

There are few recent data on epidemiology of ADRs.3 In the United Kingdom, most studies were performed 10 to 30 years ago and were relatively small, often confined to individual units such as for care of the elderly.4-11 The largest UK study was based on retrospective review of case notes,12 and, given the poor documentation of ADRs in medical case notes, it probably underestimated the impact. Of the two most recent UK studies, one concentrated on an acute medical admissions unit,13 while another had broad inclusion criteria for drug related admissions, including overdoses.14 Given the changes in medical practice over the past two decades, more recent estimates of the burden of ADRs on hospitals are needed. We undertook a prospective analysis of admissions caused by ADRs in two large UK hospitals to define prevalence and outcome and to assess causality and preventability.

Methods

The study was conducted from November 2001 to April 2002 in two NHS hospitals in Merseyside: hospital A—a teaching hospital serving a population of 300 000—and hospital B—a district general hospital, serving a population of 330 000. To ensure that there was consistency between the two sites, in hospital B, we excluded patients aged < 16 years and women presenting with obstetric or gynaecological complaints.

We assessed every patient aged over 16 years who was admitted over the six month period to determine if the admission had been caused by an ADR. Most patients were admitted through either the accident and emergency department or the acute medical and surgical assessment units. The definition of ADR used was that of Edwards and Aronson.15 We did not include any patients with either deliberate or unintentional overdose or those who relapsed because of non-compliance. Patients were categorised as having an ADR by either SM (in hospital A) or SJ (in hospital B) if the cause of admission was consistent with the known adverse effect profile of the drug (according to the British National Formulary16), if there was temporal relation with the start of drug therapy, and if, after appropriate investigations, other causes were excluded. When the drug history was unclear, we interviewed the patients or relatives or obtained further details from the general practitioner. All patients initially categorised as having an ADR were assessed again by two or three of the authors, who met to reach a consensus decision and exclude doubtful cases (n = 30, 2.4%). MP undertook a further review of all ADR cases to ensure correct categorisation. Assessment of causality was also performed for all cases using the methods of Naranjo et al17 and Jones.18 To ensure that patients with ADRs had not been missed, from each hospital we analysed 200 random case notes (400 in total) of patients categorised as not having had an ADR. All assessments were performed by staff with training in drug safety, including specialists in clinical pharmacology and general medicine, pharmacy, geriatrics, and nursing.

Where the patient was categorised as having an ADR, we recorded all drug details, the nature of the reaction, the outcome, the total time spent in hospital, and any invasive investigations performed. In addition, we determined the type of ADR (according to the classification of Rawlins and Thompson19) and whether it was due to an interaction (according to the interactions listed in the summary of product characteristics or relevant literature, or both).

We assessed avoidability of the ADRs using the definitions developed by Hallas et al,20 as follows:

  • Definitely avoidable—the ADR was due to a drug treatment procedure inconsistent with present day knowledge of good medical practice
  • Possible avoidable—the ADR could have been avoided by an effort exceeding the obligatory demands of present day knowledge of good medical practice
  • Unavoidable—the ADR could not have been avoided by any reasonable means.

Statistical analysis
Statistical analysis was performed with the StatsDirect statistical software program (version 1.9.8). The results are presented either as medians and interquartile ranges or percentage frequencies and 95% confidence intervals, as appropriate. Statistical analysis was performed with the Mann-Whitney U test for all data, except for proportions, which were analysed by the z test. A P value < 0.05 was regarded as being significant.

Results

Over six months there were 18 820 admissions (7911 in hospital A; 10 909 in hospital B). Events judged as being due to an ADR caused 1225 (6.5%, 95% confidence interval 6.2% to 6.9%) admissions. Patients admitted with ADRs (median age 76 years, interquartile range 65-83) were significantly older than patients without ADRs (66 years, 46-79; 95% confidence interval for difference 8 years to 10 years, P < 0.0001). The proportion of women in the ADR group (59%) was significantly higher than in the non-ADR group (52%; z = 4.9; 4% to 10%, P < 0.0001). The admission rate for ADR in hospital A (n = 564, 7.1%) was slightly but significantly higher than in hospital B (n = 661, 6.1%; z = 3.0, 0.4% to 1.8%; P = 0.003). Eighty percent (n = 980; 78% to 82%) of the ADRs were judged to have been directly responsible for the admission (termed "causal"), while 20% (n = 245, 18% to 22%) were identified through screening (termed "coincidental"), and, although not directly responsible for the admission, may nevertheless have contributed to it. Most ADRs (n = 1161, 95%, 93% to 96%) were classified as type A ADRs, according to the classification of Rawlins and Thompson.19 In our review of 400 admissions categorised as not being related to an ADR we did not identify any misclassified patients, indicating that the proportion of false negatives was probably below 1/133.

We determined avoidability of admissions related to an ADR by the method of Hallas et al.20 Only 340 (28%, 25% to 30%) of the ADR were assessed as unavoidable, while 107 (9%, 7% to 10%) and 773 (63%, 60% to 66%) were classified as "definitely avoidable" and "possibly avoidable," respectively. Thus, we classified 72% of ADRs as avoidable.

We used two forms of assessment of causality for all admissions categorised as due to an ADR.17 18 Most admissions were classified as "probable" (table 1). There was agreement between the two assessments in 1069 (87%) of the admissions.


View this table:
[in this window]
[in a new window]
  		Table 1 Assessment of causality of all admissions related to adverse drug reaction. Figures are numbers (percentages) of admissions

 

Table 2 shows the outcome of the patients admitted with ADRs. Although most patients recovered, 28 (2.3%) died as a direct result of the index ADR (as detailed in either the case notes or on the death certificate). Gastrointestinal bleeding was responsible for 15 (54%) deaths (table 3), while aspirin, in isolation or in combination with other drugs, was implicated in 17 (61%) deaths. ADRs were therefore responsible for the death of 0.15% (0.1% to 0.2%) of all the patients admitted.


View this table:
[in this window]
[in a new window]
  		Table 2 Outcome of patients admitted to hospital with adverse drug reaction

 

View this table:
[in this window]
[in a new window]
  		Table 3 Details of deaths caused by adverse drug reactions

 

Patients admitted with an ADR had a median stay of eight days (interquartile range 4-18 days), and the total bed occupancy in the two hospitals was substantial (table 2). The cost of this at average costs per medical bed day (£228; {euro}343, $414))21 would be £466m ({euro}706m, $847m) a year.

Table 4 lists the drugs implicated in causing ADRs. Non-steroidal anti-inflammatory drugs (NSAIDs) and diuretics were most commonly implicated. Aspirin was the most common drug, implicated in 18% of admissions. In these admissions 162 (74%) patients were taking a dose of 75 mg daily. Gastrointestinal bleeding was the most common adverse effect, occurring in 157 (72%) of all aspirin related admissions.


View this table:
[in this window]
[in a new window]
  		Table 4 Drugs causing adverse drug reactions

 

Interactions were responsible for ADRs in 88 (15.6%, 13% to 19%) and 115 (17.4%, 15% to 21%) of the admissions in hospitals A and B, respectively. Overall, interactions accounted for 16.6% (15% to 19%) of ADRs. Examples of interactions included aspirin with warfarin causing gastrointestinal bleeding, aspirin with other NSAIDs leading to gastrointestinal adverse effects, renal failure associated with the use of combinations of diuretics or the concomitant use of diuretics and ACE inhibitors, and increased anticoagulation and digoxin toxicity through coprescription of interacting drugs.

Discussion

We have undertaken the largest prospective analysis in the United Kingdom of adverse drug reactions (ADRs) as a cause of admission to hospital. Our data show that up to 6.5% or 5.2% (if the fifth of ADRs detected coincidently are excluded) of all admissions are related to ADRs. This is similar to the 5% estimate based on pooled data from several studies worldwide.22 Many of the studies included in recent systematic reviews, however, are more than 20 years old,1 3 23 24 and it is disappointing that the burden of ADRs has not decreased.

Study design—strengths and weaknesses
The advantages of our study over earlier work include the prospective nature and size, which allowed a more accurate recording of both the drug history and symptoms, and the assessment of causality. However, as with any other study of this nature, there is a potential weakness in that assignment of an admission as being related to an ADR is subject to clinical judgment, which may vary between individuals. To overcome this, we assessed all patients at least twice, and we subjected all the cases to two validated assessments of causality,17 18 which showed a high degree of agreement. Nevertheless, it is impossible to be absolutely certain of a causal link between a drug and an ADR. For example, with low dose aspirin, up to half of the cases of bleeding may have occurred anyway, irrespective of aspirin use.25 However, it is important to remember that such figures are derived from population based studies and such assessment is not always possible in individual patients.

Burden of ADRs on bed occupancy and cost
Patients with an ADR stayed a median of eight days. Extrapolating this to the whole NHS bed base in England for patients aged > 16 years suggests that at any one time the equivalent of up to seven 800 bed hospitals may be occupied by patients admitted with ADRs. This is higher than the estimate in a recent systematic review (four to six 400 bed hospitals),3 which was based on shorter hospital stays derived from smaller studies. However, it is important to exercise caution in interpreting this estimate of bed use as it is based on extrapolation from two hospitals to the whole NHS bed base, we were not able to determine the causative fractions for all the implicated drugs, and the estimate does not take into account the bed days saved through the beneficial effects of the drugs.

Our data suggest that admissions related to ADRs cost the NHS up to £466m annually. Although estimates of costs in the literature vary,26 on a per capita basis our figure is comparable with the lower estimates from the United States27 28 and also with a total costs estimated in a recent UK systematic review.3 Further detailed analysis, however, is required to provide more accurate figures.

Drugs implicated in ADRs
Lazarou et al suggested that ADRs, based on a death rate of 0.32%, caused over 100 000 deaths in the United States.1 This figure was based on a 0.13% incidence of fatal ADRs in patients admitted to hospital, and 0.19% in patients developing an ADR while in hospital. Our analysis of hospital admissions related to ADRs suggests a 0.15% incidence of fatal ADRs, similar to the US figure.1 More recent data are needed to determine the prevalence of ADR after admission to hospital. In 2002 in England there were a total of 3.8 million acute admissions,29 suggesting that ADRs causing hospital admission are responsible for the death of 5700 patients (3800 to 7600) every year. The true rate of death taking into account all ADRs (those causing admission, and those occurring while patients are in hospital) may therefore turn out to be greater than 10 000 a year.

Aspirin was identified as a causal agent in 18% of cases of all admissions for ADRs, while other NSAIDs and diuretics were implicated in 12% and 27%, respectively. This is consistent with results of previous studies.3 The finding that low dose aspirin was the most common drug implicated is relatively novel. However, caution has to be exercised in interpreting these data for two reasons: firstly, we do not have consumption data for these drugs, and the rank order of the implicated drugs may be a reflection of how commonly they are used. Secondly, we have concentrated on harms and have not taken into account the benefits of the drugs. This may be particularly true for drugs such as low dose aspirin, for which convincing data exist of the long terms benefits of prophylactic use in high risk patients.30 Nevertheless, measures that can further improve the benefit:harm ratio and avoid some of these ADRs need to be put into place. Our data would suggest that over 70% of the ADRs in this study were either possibly or definitely avoidable. Although we have used a previously described method,20 its weakness is that it does require a degree of clinical judgment, which may have differed with other investigators. Nevertheless, it is consistent with recent data from France31 and the United Kingdom,13 which showed that 80% and 67% of ADRs, respectively, were preventable. It is also compatible with a recent meta-analysis, where the rate of preventable ADRs was 59% (interquartile range 50-73%).23

Improving benefit:harm ratio
Given our findings and those in the literature, it is therefore incumbent on prescribers to determine the need for a particular drug in a patient and to use this drug at the lowest dose necessary to achieve benefit. Indeed, Langman has calculated that deaths related to aspirin could be reduced by 30% with the lower dose of 75 mg.32 However, even this dose can result in substantial morbidity and mortality, and other measures are needed. For example, regular use of proton pump inhibitors or misoprostol may be a cost effective method of reducing gastrointestinal adverse events associated with NSAIDs.26 Given that elderly people seem to be at higher risk of ADRs, many of the recommendations in the National Service Framework for the elderly need to be implemented.33 Simple measures such as regular review of prescriptions, the use of computerised prescribing, and the involvement of pharmacists in assessing prescribing behaviour may all reduce the burden caused by ADRs. In this respect, it is important to highlight that interactions accounted for one in six of the ADRs in this study.

In conclusion, ADRs are an important cause of hospital admissions, resulting in a considerable use of the NHS bed base, and a significant number of deaths. Many may be preventable through simple improvements in prescribing. We concentrated on ADRs causing hospital admissions and did not evaluate the burden caused by ADR occurring while patients are in hospital, or ADRs in primary care that did not result in hospital admission, which may at least double the figures presented here. Measures are urgently needed to reduce the burden on the NHS.


What is already known on this topic

Adverse drug reactions (ADRs) account for 5% of hospital admissions, although this figure is largely based on small studies, many of which were performed before 1990

The incidence of fatal reactions in all patients admitted to hospital has been reported to be 0.13%, but this is based on a meta-analysis of studies that were mostly performed several decades ago

What this study adds

ADRs continue to represent a considerable burden on the NHS, accounting for 1 in 16 hospital admissions and 4% of the hospital bed capacity

Most ADRs were predictable from the known pharmacology of the drugs and many represented known interactions and are therefore likely to be preventable.

Over 2% of patients admitted with an adverse drug reaction died, suggesting that adverse effects may be responsible for the death of 0.15% of all patients admitted

Older drugs continue to be most commonly implicated in causing such admissions


We thank June Raine (MHRA) for her encouragement and assistance with this study, all staff in both hospitals who assisted with the study, and, in particular, S Roberts, S Morrison-Griffiths, and R Brady for their help in identifying case notes and in data extraction.

Contributors: MP, TJW, BKP, and AMB devised the idea of the study, while MP and AMB raised funding. MP oversaw the whole study. SJ and SM collected the data and input the data into databases. AKS, CG, and KF were responsible for study implementation, and review and supervision of the data collection in hospital B; MP and AMB undertook the same roles in hospital A. The analyses were carried out independently by MP and SJ, and verified by TJW. MP produced the first draft, and all authors contributed to the final draft of the manuscript. MP is guarantor for the study.

Funding: The study was funded by the MHRA (Medicines and Healthcare Products Regulatory Agency; formerly the Medicines Control Agency). The MHRA had no role in data interpretation or in the production of this manuscript.

Competing interests: At the time of the study, AMB was chairman of the Committee on Safety of Medicines and now is chairman of the MHRA. MP is a member of the Committee on Safety of Medicines and of the subcommittee on pharmacovigilance. BKP is a member of the Committee on Safety of Medicines.

Ethical approval: Liverpool Local Research Ethics Committee and Wirral Health Authority Research Ethics Committee.

References

  1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients—a meta-analysis of prospective studies. JAMA 1998;279: 1200-5.[Abstract/Free Full Text]
  2. Kvasz M, Allen IE, Gordon MJ, Ro EY, Estok R, Olkin I, et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. MedGenMed 2000;2: E3.[Medline]
  3. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier Extra 2002;June: 1-16.
  4. Ghose K. Hospital bed occupancy due to drug-related problems. J R Soc Med 1980;73: 853-6.[Web of Science][Medline]
  5. Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984;ii: 564-7.
  6. Hurwitz N. Admissions to hospital due to drugs. BMJ 1969;i: 539-40.
  7. Hurwitz N. Predisposing factors in adverse reactions to drugs. BMJ 1969;i: 536-9.
  8. Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969;i: 531-6.
  9. Leach S, Roy SS. Adverse drug reactions: an investigation on an acute geriatric ward. Age Ageing 1986;15: 241-6.[Abstract/Free Full Text]
  10. Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicentre investigation. Age Ageing 1980;9: 73-80.[Abstract/Free Full Text]
  11. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992;21: 294-300.[Abstract/Free Full Text]
  12. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996;42: 423-9.[CrossRef][Web of Science][Medline]
  13. Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003;12: 280-5.[Abstract/Free Full Text]
  14. Bhalla N, Duggan C, Dhillon S. The incidence and nature of drug-related admissions to hospital. Pharmaceutical J 2003;270: 583-6.
  15. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356: 1255-9.[CrossRef][Web of Science][Medline]
  16. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA, RPS, 2002 (No 44).
  17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberst EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239-45.[Web of Science][Medline]
  18. Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health 1982;5: 58-67.[Medline]
  19. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991: 18-45.
  20. Hallas J, Harvald B, Gram LF, Grodum E, Prosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990;228: 83-90.[Web of Science][Medline]
  21. Chartered Institute of Public Finance and Accountancy (CIPFA). The health service financial database and comparative tool. Croydon: Institute of Public Finance, 2002.
  22. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27: 832-40.[Abstract]
  23. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother 2002;36: 1238-48.[Abstract]
  24. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002;24: 46-54.[CrossRef][Web of Science][Medline]
  25. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310: 827-30.[Abstract/Free Full Text]
  26. Rodriguez-Monguio R, Otero M, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003;21: 623-50.[CrossRef][Web of Science][Medline]
  27. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997;277: 307-11.[Abstract/Free Full Text]
  28. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277: 301-6.[Abstract/Free Full Text]
  29. Department of Health. Hospital episode statistics 2001-2. www.doh.gov.uk/hes/free_data/index.html (accessed 13 Nov 2003).
  30. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346: 1800-6.[Abstract/Free Full Text]
  31. Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000;56: 181-6.[CrossRef][Web of Science][Medline]
  32. Langman MJ. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Saf 2001;10: 13-9.[CrossRef][Web of Science][Medline]
  33. Department of Health. Medicines for older people: implementing medicines-related aspects of the NSF for older people. London: Department of Health, 2001.
(Accepted 11 June 2004)


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study
Min Zhang, C D’Arcy J Holman, Sylvie D Price, Frank M Sanfilippo, David B Preen, and Max K Bulsara
BMJ 2009 338: a2752. [Abstract] [Full Text] [PDF]

Readmissions as a result of adverse drug reactions in older people
Susan Morgan
BMJ 2009 338: a2436. [Extract] [Full Text]

A substantial cause of preventable illness
Jerry Avorn and William H Shrank
BMJ 2008 336: 956-957. [Full Text] [PDF]

A prescription for better prescribing
Jeffrey K Aronson, Graeme Henderson, David J Webb, and Michael D Rawlins
BMJ 2006 333: 459-460. [Extract] [Full Text] [PDF]

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
Sarah E McDowell, Jamie J Coleman, and R E Ferner
BMJ 2006 332: 1177-1181. [Abstract] [Full Text] [PDF]

Adverse drug reactions result in 250 000 UK admissions a year
Lisa Hitchen
BMJ 2006 332: 1109. [Extract] [Full Text] [PDF]

Best practices for safe handling of products containing concentrated potassium
Michelle Tubman, Sumit R Majumdar, Daniel Lee, Carol Friesen, and Terry P Klassen
BMJ 2005 331: 274-277. [Extract] [Full Text] [PDF]

Drug safety and regulation
Patrick C Waller, Stephen J W Evans, and Keith Beard
BMJ 2005 331: 4-5. [Extract] [Full Text] [PDF]

Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70
Mark R Nelson, Danny Liew, Melanie Bertram, and Theo Vos
BMJ 2005 330: 1306. [Abstract] [Full Text] [PDF]

Who needs health care—the well or the sick?
Iona Heath
BMJ 2005 330: 954-956. [Extract] [Full Text] [PDF]

Assessing drug safety
Nicholas Moore
BMJ 2005 330: 539-540. [Extract] [Full Text]

NICE and its value judgments: Option of safe "understudy" treatments should be available
Woody Caan
BMJ 2004 329: 740. [Extract] [Full Text] [PDF]

Adverse drug reactions as cause of admission to hospital: Alcohol and other non-prescribed drugs may have impact on adverse drug reactions
Edwina R L Williams and Ruth E Taylor
BMJ 2004 329: 459. [Extract] [Full Text]

Adverse drug reactions as cause of admission to hospital: Not all drugs that cause adverse reactions are actually prescribed by doctors
Daniel J Saunders
BMJ 2004 329: 459. [Extract] [Full Text]

Adverse drug reactions as cause of admission to hospital: Definition of adverse drug reactions needs to include overdose
M Barton Laws
BMJ 2004 329: 459-460. [Extract] [Full Text]

Adverse drug reactions as cause of admission to hospital: Only part of the picture was reported for aspirin
Mano Joseph
BMJ 2004 329: 459. [Extract] [Full Text]

Adverse drug reactions as cause of admission to hospital: Admissions to ear, nose, and throat departments were not mentioned
Nicholas J Calder and Duncan MacDonald
BMJ 2004 329: 460. [Extract] [Full Text]

Adverse drug reactions cause too many hospital admissions
BMJ 2004 329: 0. [Full Text] [PDF]

This article has been cited by other articles:

  • Antoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G., Kitteringham, N. R., Park, B. K. (2009). High-Mobility Group Box-1 Protein and Keratin-18, Circulating Serum Proteins Informative of Acetaminophen-Induced Necrosis and Apoptosis In Vivo. Toxicol Sci 112: 521-531 [Abstract] [Full text]  
  • Watson, M. C, Cleland, J. A, Bond, C. M (2009). Simulated patient visits with immediate feedback to improve the supply of over-the-counter medicines: a feasibility study. Fam Pract 26: 532-542 [Abstract] [Full text]  
  • Deng, X., Luyendyk, J. P., Ganey, P. E., Roth, R. A. (2009). Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models. Pharmacol. Rev. 61: 262-282 [Abstract] [Full text]  
  • Abdul-Hadi, O., Parvizi, J., Austin, M. S., Viscusi, E., Einhorn, T. (2009). Nonsteroidal Anti-Inflammatory Drugs in Orthopaedics. JBJS 91: 2020-2027 [Full text]  
  • Tangiisuran, B., Wright, J., Van der Cammen, T., Rajkumar, C. (2009). Adverse drug reactions in elderly: challenges in identification and improving preventative strategies. Age Ageing 38: 358-359 [Full text]  
  • Wadelius, M. (2009). Point: Use of Pharmacogenetics in Guiding Treatment with Warfarin. Clin. Chem. 55: 709-711 [Full text]  
  • Steinhubl, S. R., Bhatt, D. L., Brennan, D. M., Montalescot, G., Hankey, G. J., Eikelboom, J. W., Berger, P. B., Topol, E. J., on behalf of the CHARISMA Investigators, (2009). Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. ANN INTERN MED 150: 379-386 [Abstract] [Full text]  
  • Vassilev, Z. P., Chu, A. F., Ruck, B., Adams, E. H., Marcus, S. M. (2009). Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007. Am J Health Syst Pharm 66: 481-487 [Abstract] [Full text]  
  • van Doormaal, J E, van den Bemt, P M L A, Mol, P G M, Zaal, R J, Egberts, A C G, Haaijer-Ruskamp, F M, Kosterink, J G W (2009). Medication errors: the impact of prescribing and transcribing errors on preventable harm in hospitalised patients. Qual Saf Health Care 18: 22-27 [Abstract] [Full text]  
  • Zhang, M., Holman, C D. J, Price, S. D, Sanfilippo, F. M, Preen, D. B, Bulsara, M. K (2009). Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 338: a2752-a2752 [Abstract] [Full text]  
  • Morgan, S. (2009). Readmissions as a result of adverse drug reactions in older people. BMJ 338: a2436-a2436 [Full text]  
  • Elwood, P., Morgan, G. (2008). Aspirin for all over 50 revisited. Heart 94: 1364-1365 [Full text]  
  • Myers, A. L., Upreti, V. V., Khurana, M., Eddington, N. D. (2008). Characterization of Total Plasma Glycosaminoglycan Levels in Healthy Volunteers Following Oral Administration of a Novel Antithrombotic Odiparcil With Aspirin or Enoxaparin. J Clin Pharmacol 48: 1158-1170 [Abstract] [Full text]  
  • Leendertse, A. J., Egberts, A. C. G., Stoker, L. J., van den Bemt, P. M. L. A., for the HARM Study Group, (2008). Frequency of and Risk Factors for Preventable Medication-Related Hospital Admissions in the Netherlands. Arch Intern Med 168: 1890-1896 [Abstract] [Full text]  
  • Hamblin, L., Laird, A., Parkes, E., Walker, A. F. (2008). Improved arthritic knee health in a pilot RCT of phytotherapy. The Journal of the Royal Society for the Promotion of Health 128: 255-262 [Abstract]  
  • Blaha, M. J., Bansal, S., Rouf, R., Golden, S. H., Blumenthal, R. S., DeFilippis, A. P. (2008). A Practical 'ABCDE' Approach to the Metabolic Syndrome. Mayo Clin Proc. 83: 932-943 [Abstract] [Full text]  
  • Phillips, D. P., Barker, G. E. C., Eguchi, M. M. (2008). A Steep Increase in Domestic Fatal Medication Errors With Use of Alcohol and/or Street Drugs. Arch Intern Med 168: 1561-1566 [Abstract] [Full text]  
  • Zed, P. J. PharmD, Abu-Laban, R. B. MD MHSc, Balen, R. M. PharmD, Loewen, P. S. PharmD, Hohl, C. M. MD, Brubacher, J. R. MD MSc, Wilbur, K. PharmD, Wiens, M. O. BSc(Pharm), Samoy, L. J. BSc(Pharm), Lacaria, K. BSc(Pharm), Purssell, R. A. MD (2008). Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 178: 1563-1569 [Abstract] [Full text]  
  • Huang, S.-M., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K., Burckart, G. J., Chung, S., Colangelo, P., Frucht, D., Green, M. D., Hepp, P., Karnaukhova, E., Ko, H.-S., Lee, J.-I., Marroum, P. J., Norden, J. M., Qiu, W., Rahman, A., Sobel, S., Stifano, T., Thummel, K., Wei, X.-x., Yasuda, S., Zheng, J. H., Zhao, H., Lesko, L. J. (2008). New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process. J Clin Pharmacol 48: 662-670 [Abstract] [Full text]  
  • Avorn, J., Shrank, W. H (2008). A substantial cause of preventable illness. BMJ 336: 956-957 [Full text]  
  • Isacson, D., Johansson, L., Bingefors, K. (2008). Nationwide Survey of Subjectively Reported Adverse Drug Reactions in Sweden. The Annals of Pharmacotherapy 42: 347-353 [Abstract] [Full text]  
  • MacBride-Stewart, S. P, Elton, R., Walley, T. (2008). Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Fam Pract 0: cmm074v1-cmm074 [Abstract] [Full text]  
  • Tremlett, H.L., Oger, J. (2008). Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler 14: 94-105 [Abstract]  
  • Munro, A J (2007). Hidden danger, obvious opportunity: error and risk in the management of cancer. Br. J. Radiol. 80: 955-966 [Full text]  
  • Rivkin, A. (2007). Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 64: 1840-1843 [Abstract] [Full text]  
  • Cresswell, K. M., Fernando, B., McKinstry, B., Sheikh, A. (2007). Adverse drug events in the elderly. Br Med Bull 83: 259-274 [Abstract] [Full text]  
  • Thomsen, L. A., Winterstein, A. G, Sondergaard, B., Haugbolle, L. S., Melander, A. (2007). Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care. The Annals of Pharmacotherapy 41: 1411-1426 [Abstract] [Full text]  
  • van Leen, M. W. F., van der Eijk, I., Schols, J. M. G. A. (2007). Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. Age Ageing 36: 414-418 [Abstract] [Full text]  
  • Campbell, C. L., Smyth, S., Montalescot, G., Steinhubl, S. R. (2007). Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review. JAMA 297: 2018-2024 [Abstract] [Full text]  
  • Kramer, J. S., Hopkins, P. J., Rosendale, J. C., Garrelts, J. C., Hale, L. S., Nester, T. M., Cochran, P., Eidem, L. A., Haneke, R. D. (2007). Implementation of an electronic system for medication reconciliation. Am J Health Syst Pharm 64: 404-422 [Abstract] [Full text]  
  • Maidment, I. D, Lelliott, P., Paton, C. (2006). Medication errors in mental healthcare: a systematic review. Qual Saf Health Care 15: 409-413 [Abstract] [Full text]  
  • Gorard, D.A. (2006). Escalating polypharmacy. QJM 99: 797-800 [Abstract] [Full text]  
  • Harris, C. L, Raisch, D. W, Abhyankar, U., Marfatia, S., Campbell, H. M, Sather, M. R (2006). GI Risk Factors and Use of GI Protective Agents Among Patients Receiving Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy 40: 1924-1931 [Abstract] [Full text]  
  • Macdonald, D J M, Tollan, C J, Robertson, I, Rana, B S (2006). Massive haemorrhage after a low-energy pubic ramus fracture in a 71-year-old woman.. Postgrad. Med. J. 82: e25-e25 [Abstract] [Full text]  
  • Aronson, J. K, Henderson, G., Webb, D. J, Rawlins, M. D (2006). A prescription for better prescribing.. BMJ 333: 459-460 [Full text]  
  • Hassett, M. J., O'Malley, A. J., Pakes, J. R., Newhouse, J. P., Earle, C. C. (2006). Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.. JNCI J Natl Cancer Inst 98: 1108-1117 [Abstract] [Full text]  
  • McDowell, S. E, Coleman, J. J, Ferner, R E (2006). Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332: 1177-1181 [Abstract] [Full text]  
  • Hitchen, L. (2006). Adverse drug reactions result in 250,000 UK admissions a year.. BMJ 332: 1109-1109 [Full text]  
  • (2006). Non-medical prescribing. DTB 44: 33-37 [Abstract] [Full text]  
  • Morris, C J, Cantrill, J A, Avery, A J, Howard, R L (2006). Preventing drug related morbidity: a process for facilitating changes in practice.. Qual Saf Health Care 15: 116-121 [Abstract] [Full text]  
  • Wang, Y-T, Chou, H-H, Chen, F-F, Chen, M-J, Chiou, Y-Y (2006). A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: just a coincidence?. Lupus 15: 244-247 [Abstract]  
  • Gruchalla, R. S., Pirmohamed, M. (2006). Antibiotic Allergy. NEJM 354: 601-609 [Full text]  
  • Kirshner, H. S., Biller, J., Callahan, A. S. III (2005). Long-Term Therapy to Prevent Stroke. J Am Board Fam Med 18: 528-540 [Abstract] [Full text]  
  • Yeom, J. H., Park, J. S., Oh, O.-H., Shin, H. T., Oh, J. M. (2005). Identification of Inappropriate Drug Prescribing by Computerized, Retrospective DUR Screening in Korea. The Annals of Pharmacotherapy 39: 1918-1923 [Abstract] [Full text]  
  • Zed, P. J. (2005). Drug-Related Visits to the Emergency Department. Journal of Pharmacy Practice 18: 329-335 [Abstract]  
  • Willard, H. F, Angrist, M., Ginsburg, G. S (2005). Genomic medicine: genetic variation and its impact on the future of health care. Phil Trans R Soc B 360: 1543-1550 [Abstract] [Full text]  
  • Tubman, M., Majumdar, S. R, Lee, D., Friesen, C., Klassen, T. P (2005). Best practices for safe handling of products containing concentrated potassium. BMJ 331: 274-277 [Full text]  
  • Benahmed, S., Picot, M.-C., Dumas, F., Demoly, P. (2005). Accuracy of a Pharmacovigilance Algorithm in Diagnosing Drug Hypersensitivity Reactions. Arch Intern Med 165: 1500-1505 [Abstract] [Full text]  
  • Waller, P. C, Evans, S. J W, Beard, K. (2005). Drug safety and regulation. BMJ 331: 4-5 [Full text]  
  • Gottlieb, S. (2005). Opening Pandora's Pillbox: Using Modern Information Tools To Improve Drug Safety. Health Aff (Millwood) 24: 938-948 [Abstract] [Full text]  
  • Bodin, L., Verstuyft, C., Tregouet, D.-A., Robert, A., Dubert, L., Funck-Brentano, C., Jaillon, P., Beaune, P., Laurent-Puig, P., Becquemont, L., Loriot, M.-A. (2005). Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106: 135-140 [Abstract] [Full text]  
  • Nelson, M. R, Liew, D., Bertram, M., Vos, T. (2005). Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged >=70. BMJ 330: 1306- [Abstract] [Full text]  
  • Morris, C J, Savelyich, B S P, Avery, A J, Cantrill, J A, Sheikh, A (2005). Patient safety features of clinical computer systems: questionnaire survey of GP views. Qual Saf Health Care 14: 164-168 [Abstract] [Full text]  
  • Lin, P. J. (2005). Reviewing the reality: why we need to change. Eur Heart J Suppl 7: E15-E20 [Full text]  
  • Heath, I. (2005). Who needs health care--the well or the sick?. BMJ 330: 954-956 [Full text]  
  • Moore, N. (2005). Assessing drug safety. BMJ 330: 539-540 [Full text]  
  • Alberts, D. S., Potter, J. D., Martinez, M. E., Hess, L. M., Stopeck, A., Lance, P. (2005). What Happened to the Coxibs on the Way to the Cardiologist?. Cancer Epidemiol. Biomarkers Prev. 14: 555-556 [Full text]  
  • Corrigan, O P (2005). Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report. J. Med. Ethics 31: 144-148 [Abstract] [Full text]  
  • Holland, R., Lenaghan, E., Harvey, I., Smith, R., Shepstone, L., Lipp, A., Christou, M., Evans, D., Hand, C. (2005). Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ 330: 293- [Abstract] [Full text]  
  • (2004). Admissions for ADRs are as high as ever. Qual Saf Health Care 13: 466-466 [Full text]  
  • (2004). Hit parade. BMJ 329: 806-806 [Full text]  
  • (2004). Hospital Admissions for Adverse Drug Reactions. JWatch Gastroenterology 2004: 10-10 [Full text]  
  • Caan, W. (2004). NICE and its value judgments: Option of safe "understudy" treatments should be available. BMJ 329: 740-740 [Full text]  
  • (2004). Hospital Admissions for Adverse Drug Reactions Still Common. Journal Watch Cardiology 2004: 5-5 [Full text]  
  • Williams, E. R L, Taylor, R. E (2004). Adverse drug reactions as cause of admission to hospital: Alcohol and other non-prescribed drugs may have impact on adverse drug reactions. BMJ 329: 459-459 [Full text]  
  • Calder, N. J, MacDonald, D. (2004). Adverse drug reactions as cause of admission to hospital: Admissions to ear, nose, and throat departments were not mentioned. BMJ 329: 460-460 [Full text]  
  • Saunders, D. J (2004). Adverse drug reactions as cause of admission to hospital: Not all drugs that cause adverse reactions are actually prescribed by doctors. BMJ 329: 459-459 [Full text]  
  • Laws, M B. (2004). Adverse drug reactions as cause of admission to hospital: Definition of adverse drug reactions needs to include overdose. BMJ 329: 459-460 [Full text]  
  • Joseph, M. (2004). Adverse drug reactions as cause of admission to hospital: Only part of the picture was reported for aspirin. BMJ 329: 459-459 [Full text]  
  • (2004). Hospital Admissions for Adverse Drug Reactions. JWatch General 2004: 4-4 [Full text]  
  • Cuervo, L. G., Aronson, J. K (2004). The road to health care. BMJ 329: 1-2 [Full text]  

Rapid Responses:

Read all Rapid Responses

Inclusive definition of Adverse Drug Reactions
M. Barton Laws
bmj.com, 2 Jul 2004 [Full text]
Part of the picture
Mano Joseph
bmj.com, 3 Jul 2004 [Full text]
ENT admissions associated with adverse drug reactions
Nicholas J Calder, et al.
bmj.com, 5 Jul 2004 [Full text]
Adverse Drug Reactions in High Cardiovascular Risk Patients
Abdullah A Mohammed
bmj.com, 6 Jul 2004 [Full text]
Immune mediated hypersensitivity-an important cause of adverse drug events
Nasreen Khan, et al.
bmj.com, 6 Jul 2004 [Full text]
A survey of patients knowledge of NSAID side effects
Jeremy C Gibson
bmj.com, 6 Jul 2004 [Full text]
Medicine-related problems are a broader concept than ADRs
M. Isabel Baena, et al.
bmj.com, 7 Jul 2004 [Full text]
Two important things we need to know from the Study
Dipankar Choudhury
bmj.com, 8 Jul 2004 [Full text]
Re: Not all drugs which cause ADRs are actually prescribed by doctors
Daniel J Saunders
bmj.com, 9 Jul 2004 [Full text]
A view from General Practice
J. Alan Fisher
bmj.com, 12 Jul 2004 [Full text]
Another view from General Practice
L Sam Lewis
bmj.com, 13 Jul 2004 [Full text]
denominators and numerators
Matthew P Doogue
bmj.com, 13 Jul 2004 [Full text]
Adverse drug reactions in Japan
Hidekatsu Yanai, et al.
bmj.com, 13 Jul 2004 [Full text]
Yet another view from General Practice
Robert G Bunney
bmj.com, 14 Jul 2004 [Full text]
Alcohol and other non prescribed drugs - their impact on Adverse Drug Reactions
Edwina R L Williams, et al.
bmj.com, 14 Jul 2004 [Full text]
Are drug dosage regimes as optimal as they could be?
Dr Marie B McDevitt
bmj.com, 15 Jul 2004 [Full text]
Adverse Drug Reactions and Kounis Syndrome
Nicholas G. Kounis, et al.
bmj.com, 19 Jul 2004 [Full text]
Hospital admissions caused by adverse drug reactions: the Swiss pendant
Andreas Perren
bmj.com, 23 Jul 2004 [Full text]
Reducing adverse drug reactions
Martin J Kendall, et al.
bmj.com, 27 Jul 2004 [Full text]
Incorrect prescribing causes unnecessary hospitalisation too
Daniel J Vernon, et al.
bmj.com, 17 Aug 2004 [Full text]
Warfarin is a major cause of adverse drug reactions leading to hospitalisation
E Sarah Green, et al.
bmj.com, 20 Aug 2004 [Full text]
Complementary medicine and adverse reactions
Fabio Firenzuoli, et al.
bmj.com, 26 Aug 2004 [Full text]
Where orthodoxy chokes freedom of dissent
Dr. Herbert H. Nehrlich
bmj.com, 27 Aug 2004 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ